Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: An analysis of four statistical models

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 3, 1996, Pages 543-547

  Spevack, Les ^a,b   Killion, Linza T ^a   West Jr , James C ^a   Rooker, Gina M ^a   Brewer, E Allan ^a   Cuddy, Paul G ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b NONE   (Canada)

Author keywords

Antigens; Lymph node excision; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL MODEL;

EID: 0030059741     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02163-9     Document Type: Article

References (21)

1. Austenfeld, M. S.; Davis, B. E. New concepts in the treatment of stage D1 adenocarcinoma of the prostate. In: Smith, M. D., Jr., ed. The urologic clinics of North America. Vol. 17. Philadelphia, PA: W. B. Saunders Co; 1990:867-884.
2. Bluestein, D. L.; Bostwick, D. G.; Bergstralh, E. J.; Oesterling, J. E. Eliminating the need for bilateral pelvic lymphad-enectomy in select patients with prostate cancer. J. Urol. 151:1315-1320; 1994.
3. Brendler, C.B.; Cleeve, L.K.; Anderson, E.E.; Paulson, D.F. Staging pelvic lymphadenectomy for carcinoma of the prostate: risk vs. benefit. J. Urol. 124:849-850; 1980.
4. Gonzalez, J. A.; Levran, Z.; Diokno, A. C.; Steinert, B. W. Is pelvic CT, bone scan and pelvic lymphadenectomy necessary in the staging of prostate cancer? (Abstract 32). Presented at the 73rd Annual Meeting of the South Central Section of the American Urological Association Inc., Aug. 27-31; 1994:109 (Abstr. 32).
5. Griffith, D. P.; Rogers, E.; Dunn, K.; Ohori, M.; Scardino, P. T. The role of digital rectal examination, biopsy Gleason score and PSA in selecting patients who require pelvic lymphadenectomy for prostate cancer. Presented at the 73rd Annual Meeting of the South Central Section of the American Urological Association Inc., Aug 27-31; 1884:117 (Abstr. 40).
6. Harris, M. J.; Bishoff, J. T.; Reyes, A.; Thompson, I. M. Preoperative PSA and prostate biopsy Gleason's grade predictive of benign pelvic lymph nodes in men with prostate cancer. J. Urol. 151:451; 1994 (Abstr. 340A).
7. Kavoussi, L. R. Techniques for nodal staging in prostate cancer. Editorial. J. Urol. 151:1324-1325; 1994.
8. Kleer, E.; Larson-Keller, J. J.; Zincke, H.; Oesterling, J. E. Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy. Urology 41:207-216; 1993.
9. Kramer, S. A.; Spahr, J.; Brendler, C. B.; Glenn, J. F.; Paulson, D. F. Experience with Gleason histopathologic grading in prostate cancer. J. Urol. 124:223-225; 1980.
10. Morgan, W. R.; Lieber, M. M. Pelvic lymphadenectomy. In: Crawford, E. D.; Das, S., eds. Current genitourinary cancer surgery. Philadelphia, PA: Lea & Febiger; 1990:162-169.
11. Narayan, P.,; Fournier, G.; Gajendran, V.; Leidich, R.; Lo, R.; Wolf, J. S., Jr.; Jacob, G.; Nicolaisen, G.; Palmer, K.; Freiha, F. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason Score in predicting risk of pelvic lymph node metastasis in prostate cancer. Urology 44(4):519-524; 1994.
12. Osterling, J. E.; Brendler, C. B.; Epstein, J. I.; Kimball, A. W., Jr.; Walsh, P. C. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol. 138:92-98; 1987.
13. Partin, A. W.; Carter, H. B.; Chan, D. W.; Epstein, J. I.; Oesterling, J. E.; Rock, R. C.; Weber, J. P.; Walsh, P. C. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143:747-752; 1990.
14. Partin, A. W.; Epstein, J. I.; Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J. Urol. 150:110-114; 1993.
15. Partin, A. W.; Yoo, J.; Carter, H. B.; Pearson, J. D.; Chan, D. W.; Epstein, J. I.; Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. Letter to the Editor. J. Urol. 150:1924; 1993.
16. Rana, A.; Karamanis, K.; Lucas, M. G.; Chisholm, G. D. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br. J. Urol. 69:277-281; 1992.
17. Roach, M., III. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. Letter to the Editor. J. Urol. 150:1923; 1993.
18. Roach, M., III; Marquez, C.; Hae-Sook, Y.; Narayan, P.; Coleman, L.; Nseyo, U. O.; Navvab, Z.; Carroll, P. R. Predicting the risk of lymph node involvement using pre treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28:33-37; 1993.
19. Schroeder, F. H.; Hermanek, P.; Denis, L.; Fair, W. R.; Gospodarowicz, M. K.; Pavone-Macaluso, M. The TMN classification of prostate cancer. Prostate Suppl. 4:129; 1992.
20. Van Poppel, H.; Ameye, F.; Oyen, R.; Van De Voorde, W.; Baert, L. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J. Urol. 151:1310-1314; 1994.
21. Zincke, H.; Bergstralh, E. J.; Larson-Keller, J. J.; Farrow, G. M.; Myers, R. P.; Lieber, M. M.; Barrett, D. M.; Rife, C. C.; Gonchoroff, N. J. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 70(1):311-323; 1992.